Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 0378-6325

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 0378-6325). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure Less Than 140 Mmhg At Week 8 (Image 01)

A line graph comparing the percentage of patients with systolic blood pressure (SBP) under 140 mmHg across different baseline SBP values (140-180 mmHg) for treatments including valsartan and hydrochlorothiazide 320/25 mg, valsartan 320 mg, hydrochlorothiazide 25 mg, and placebo. The graph illustrates the efficacy of each treatment at varying baseline SBP levels.*

FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure Less Than 90 Mmhg At Week 8 (Image 02)

A line graph comparing baseline diastolic blood pressure (DBP in mmHg) on the x-axis and the percentage of DBP less than 90 mmHg on the y-axis. It compares four groups: Valsartan and Hydrochlorothiazide 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, showing their effects on DBP reduction.*

FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure Less Than 130 Mmhg At Week 8 (Image 03)

A line graph depicting the percentage of systolic blood pressure (SBP) under 130 mmHg over baseline SBP values ranging from 140 to 180 mmHg. The graph includes data for Valsartan and Hydrochlorothiazide 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, represented by distinct markers in the legend.*

FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure Less Than 80 Mmhg At Week 8 (Image 04)

A line chart showing the percentage reduction in diastolic blood pressure (DBP) from baseline compared to baseline DBP in mmHg. The chart compares four categories: Valsartan and Hydrochlorothiazide 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, each represented by different markers. The chart illustrates the effect of these treatments on DBP over a range of baseline DBP values from 90 to 110 mmHg.*

FDA Label Image

Valsartan Structural Formula (Image 05)

Chemical structure diagram of valsartan, one of the active ingredients in the combination tablet of valsartan and hydrochlorothiazide by Mylan Pharmaceuticals Inc.*

FDA Label Image

Hydrochlorothiazide Structural Formula (Image 06)

Chemical structure of valsartan and hydrochlorothiazide active ingredients depicted as molecular diagrams with labeled atoms and bonds.*

FDA Label Image

Valsartan And Hydrochlorothiazide Tablets, Usp 80 mg/12.5 mg Bottle Label (Image 07)

Label for Valsartan and Hydrochlorothiazide tablets, USP 80 mg/12.5 mg by Mylan Pharmaceuticals Inc. The film-coated tablet packaging indicates 90 count, prescription-only, with storage instructions and manufacturing details from Morgantown, WV. The label features the Mylan logo, an imprint 'V21' on the tablet image, and a barcode with NDC 0378-6321-77.*

FDA Label Image

Valsartan And Hydrochlorothiazide Tablets, Usp 160 mg/12.5 mg Bottle Label (Image 08)

Packaging label for Valsartan and Hydrochlorothiazide Tablets USP 160 mg/12.5 mg by Mylan Pharmaceuticals Inc. The label shows a round, beige film-coated tablet embossed with 'V22'. The package contains 90 tablets and includes dosage information, storage instructions, and barcode for the National Drug Code 0378-6322-77.*

FDA Label Image

Valsartan And Hydrochlorothiazide Tablets, Usp 160 mg/25 mg Bottle Label (Image 09)

Label from Mylan Pharmaceuticals Inc. for Valsartan and Hydrochlorothiazide film-coated tablets, USP, with strength 160 mg/25 mg. The label indicates 90 tablets in the package, includes NDC 0378-6323-77, and features an image of a single tablet marked 'V23.' Storage instructions and manufacturer details are also visible along with a barcode.*

FDA Label Image

Valsartan And Hydrochlorothiazide Tablets, Usp 320 mg/12.5 mg Bottle Label (Image 10)

Label for Valsartan and Hydrochlorothiazide Tablets, USP, 320 mg/12.5 mg film-coated oral tablets. The label shows the drug name, strength, and a photo of a brown oval tablet marked V24H. It includes storage instructions, manufacturer information (Mylan Pharmaceuticals Inc.), and packaging details for 90 tablets. The label also has a barcode and usage precautions.*

FDA Label Image

Valsartan And Hydrochlorothiazide Tablets, Usp 320 mg/25 mg Bottle Label (Image 11)

Packaging label for Valsartan and Hydrochlorothiazide Tablets, USP 320 mg/25 mg by Mylan Pharmaceuticals Inc. The label shows a film-coated tablet image marked V25 and indicates a 90-tablet bottle. It includes storage, dosage instructions, and a barcode, with a designated varnish-free area for coding.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.